In this week's episode, the discussion focuses on Health Minister Mark Butler's address at an event in Sydney and its invocation of history as the framework for pending negotiations over HTA reforms and PBS pricing. Also, strange comments by one senior official about evidence in healthcare decision-making send a clear signal about some of the thinking that might impact the next one to two years.

A powerful patient story was overshadowed by a mindset that expects patients to simplify their needs and accept delays. Some proposed reforms risk entrenching these problems, while claims of having a 'world-class system' gaslight patients and seek to shut down scrutiny. This is about power. Institutions hold it, and patients are expected to adapt, meaning they must not relent in their push for change.

How Australia’s health system is failing patients by prioritising process and cost control over timely access to treatment, forcing more to rely on compassionate access programs. HTA processes are slow, often dehumanising, and used by the government as a delay tactic. Meaningful reform requires shifting away from process-driven decision-making toward real patient needs. The opportunity articulated this week by one leader is to pursue a more strategic approach to policy. The episode also highlights the growing role of pharmacy, which is increasingly based on trust and confidence, especially post-COVID, in contrast to struggling GPs.

In this episode, we examine funding uncertainty for genomic profiling through OMICO, structural tensions within the PBS and pharmaceutical supply chain, and broader concerns about how political and financial incentives shape health policy and budget decisions. The episode concludes with an uncomfortable discussion of recent public commentary on hostility against some communities (trigger warning).

Australia’s system for deciding whether new health technologies are funded is too focused on contested models and not enough on real people and their needs. The lack of human consideration leads to long delays, avoidable suffering, and sometimes deaths, in a process where patient voices are 'summarised' into oblivion while insiders talk around the problem instead of fixing it quickly, openly, and based on our shared values.

Reflect on Susan Ley’s legacy as a former health minister, especially the 2015 PBS Access and Sustainability Package. She was treated rudely and unfairly, and that meaningful ecosystem reform has since stalled. Critique Senate Estimates, noting that departmental witnesses were evasive and overly defensive, with patients largely absent from the conversation. The discussion expands to reform and the lack of patient rights. Also note the troubling political rhetoric about medical information and regulation. Close by teasing upcoming upgrades to the BPD website.

Mark Butler’s four 'pillars' on medicines policy and the argument that Australia prioritises low prices over preventing shortages and ensuring access. Do we need smarter, targeted incentives to address shortages that often reflect global challenges? Is there a risk of 'process creep' that actually slows access? Aged-care reforms that unintentionally removed funding for dose administration aids and glucose monitoring.

The Government has announced an additional $25 billion for public hospitals over five years, representing close to two PBSs, while NDIS spending is still rising by $1 billion every few months. Can anyone seriously still argue that there is no new money available to invest in medicines?